Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Ariad Pharmaceuticals, Inc. : ARIA, XOMA, PRAN and NIHD added to NASDAQ Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/31/2013 | 03:15pm CET

New York, NY - (ACCESSWIRE) - 10/31/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), XOMA Corporation (NASDAQ:XOMA), Prana Biotechnology Limited (NASDAQ:PRAN) and NII Holdings Inc. (NASDAQ:NIHD)

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients is currently down (-38.13%) on 26,575,426 shares traded after Ariad suspended sales of cancer pill Iclusig. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is currently down (-90.81%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ARIA&SubId=AW

XOMA Corporation (NASDAQ:XOMA) a company that discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific is currently up (+4.35%) on 712,280 shares traded after XOMA Corporation announced very encouraging results from two Phase 2 clinical studies that are part of the Company's broad gevokizumab proof-of-concept program. XOMA Corporation (NASDAQ:XOMA) is currently up (+95.78%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about XOMA Corporation (NASDAQ:XOMA)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=XOMA&SubId=AW

Prana Biotechnology Limited (NASDAQ:PRAN) a company that researches and develops therapeutic drugs for the treatment of neurological disorders in Australia is currently up (+1.80%) on 563,051 shares traded after Prana's PBT2 Reversed Memory Loss in Normal Aging. Prana Biotechnology Limited (NASDAQ:PRAN) is currently up (+161.31%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Prana Biotechnology Limited (NASDAQ:PRAN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=PRAN&SubId=AW

NII Holdings Inc. (NASDAQ:NIHD) a company that through its subsidiaries, provides wireless communication services under the Nextel brand name to businesses and individuals in Mexico, Brazil, Argentina, Peru, and Chile is currently down (-19.58%) on 2,272,972 shares traded after NII Holdings, Inc. Discussed Q3 2013 Results. NII Holdings Inc. (NASDAQ:NIHD) is currently down (-61.3%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about NII Holdings Inc. (NASDAQ:NIHD)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=NIHD&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARIAD PHARMACEUTICALS, INC
12/08 ARIAD PHARMACEUTICALS : Announces FDA Full Approval and Label Update for Iclusig..
12/08 ARIAD PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (for..
12/07 ARIAD PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial..
12/07 ARIAD PHARMACEUTICALS : ARIADs Investigational Medicine Brigatinib Demonstrated ..
12/07 ARIAD PHARMACEUTICALS : Investigational Medicine Brigatinib Demonstrated 15.6 Mo..
12/06 ARIAD PHARMACEUTICALS : Announces Data Presentations at American Society of Hema..
12/05 ARIAD PHARMACEUTICALS : Presents Updated Brigatinib Data with 18.4 Months Median..
12/02 ARIAD PHARMACEUTICALS : to Host Webcast and Conference Call on Brigatinib Data P..
12/02 BEST BIOTECH STOCKS 2016 : The NASDAQ’s Top-Performers
11/30 ARIAD PHARMACEUTICALS, INC. (N : ARIA) Files An 8-K Other Events
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12/09 They're Definitely High On Something
12/07 ARIAD's brigatinib stops lung cancer progression for almost 16 months in mid-..
12/05 ARIAD : The Storm Has Passed
11/29 FDA fully approves ARIAD's Iclusig and a label update to include four-year fo..
11/29 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
Advertisement
Financials ($)
Sales 2016 196 M
EBIT 2016 -112 M
Net income 2016 -7,71 M
Debt 2016 152 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 13,6x
EV / Sales 2017 11,6x
Capitalization 2 521 M
More Financials
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Technical analysis trends ARIAD PHARMACEUTI...
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 13,5 $
Spread / Average Target 3,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paris Panayiotopoulos President, Chief Executive Officer & Director
Alexander John Denner Chairman
Manmeet Singh Soni Chief Financial Officer, Treasurer & Executive VP
Timothy P. Clackson Chief Scientific Officer
Nicholas Ventresca Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ARIAD PHARMACEUTICALS,..102.88%2 521
AMGEN, INC.-11.63%104 588
GILEAD SCIENCES, INC.-28.16%94 883
CELGENE CORPORATION-5.25%87 645
REGENERON PHARMACEUTIC..-31.32%38 934
ACTELION LTD50.21%21 557
More Results